A new set of studies by scientists at the Vlaams Instituut voor Biotechnologie (VIB), Vrije Universiteit Brussel (VUB) and KU Leuven has uncovered how minute molecular changes can dramatically alter the way the body processes pain and responds to certain epilepsy drugs.
Published in the journal Nature Communications, the research focuses on the TRPM3 ion channel — a protein known to play a key role in sensing pain and linked to rare neurological disorders and epilepsy.
A ‘lock-and-key’ mechanism at molecular level
Researchers identified what they describe as a tiny binding site — a “molecular keyhole” — within the TRPM3 channel. Even slight alterations in this pocket can completely change how the channel behaves.
“If you have the mirror image of your key or you make a very small change to the key or to the keyhole, suddenly the door might open or close,” said Thomas Voets, co-lead of the study.
The team examined isosakuranetin, a plant-derived compound often explored for blocking TRPM3 activity. The molecule exists in two mirror-image forms, known as S and R.
“We discovered that the active form of isosakuranetin is R, not S,” said researcher Bahar Bazeli. “R is a potent inhibitor of the channel, while S is ineffective.”
Why some treatments fail
The study goes further, showing that mutations found in some patients can alter this keyhole — effectively changing how drugs interact with the channel.
“Any small change in this pocket can affect the direction of the effect and also the efficacy,” Bazeli explained. “You can turn an antagonist into an agonist and vice versa.”
This means that in certain patients, drugs designed to block pain signals could become ineffective — or even produce the opposite effect. According to the researchers, patients with specific TRPM3 mutations “shouldn’t use the drug everyone else uses” as it may cause side effects without benefits.
Link to severe facial pain
A parallel study published in Cell Reports Medicine examined the role of TRPM3 in trigeminal neuralgia — a condition widely regarded as one of the most painful disorders.
The research found that nerve injury and inflammation significantly increase TRPM3 activity, making pain-sensing neurons hyperactive.
“Trigeminal neuralgia is one of the worst pain syndromes. People call it the suicide disease because it’s so painful,” Voets said, adding: “We show that inhibiting TRPM3 works surprisingly well in animal models.”
Genetic analysis also revealed that certain TRPM3 variants are more common in patients with the condition, suggesting a biological reason why standard treatments fail in some cases.
Toward personalised medicine
Taken together, the findings point to a shift toward more targeted therapies. By understanding how individual variations in the TRPM3 “keyhole” affect drug response, scientists say treatments could be tailored to each patient.
“Knowing exactly how a molecule fits in this lock helps a lot with developing better and more specific drugs,” Voets said. “We are now working on keys that fit even better.”
The researchers are now focusing on designing mutation-specific inhibitors — a step that could pave the way for personalised therapies for chronic pain, epilepsy and related neurological disorders.
The bigger picture
The discovery underscores how even the smallest molecular differences can have wide-ranging clinical consequences. It also highlights why a one-size-fits-all approach to treatment often fails in complex neurological conditions.
If translated into clinical practice, the “molecular keyhole” concept could mark a significant step toward precision medicine — where treatments are not just disease-specific, but tailored to the genetic profile of each patient.
Also Read:
Father’s health key to pregnancy, healthy child’s birth: Study
New Chip Helps Diagnose Heart Attacks Based on Blood Test in Minutes
Tiny ‘Keyhole’ Discovery May Transform Treatment Of Pain And Epilepsy added by Arun Kumar N on
View all posts by Arun Kumar N →